Literature DB >> 21424568

Relationship between hypermethylated MGMT gene and osteosarcoma necrosis rate after chemotherapy.

Qiu Cui1, Weihao Jiang, Jun Guo, Cheng Liu, Dingfeng Li, Xiaohong Wang, Yanjun Zeng.   

Abstract

To investigate the relativity of MGMT(O-6-methylguanine-DNA methyltransferase) gene methylation from patients with protein expression and osteosarcoma necrosis rate after chemotherapy. Fifty-one oteosarcoma tissues were collected, Methylation of MGMT gene promoter was detected by methylation-specific PCR method, and protein expression of MGMT was examined by immunohistochemistry procedure, the relationship between methylated MGMT gene expression and patients response to chemotherapy was analyzed. The positive ratio of methylation MGMT gene promoter in 51 patients was 23.5% (12 in 51). Negative percentage of protein expression of MGMT was 27.5% (14 in 51). It seemed that methylation of MGMT gene in osteosarcoma tissues had no evident relationship with the patient's age, sexuality, and the size and type of neoplasms, etc. The necrosis rates of methylated MGMT of osteosarcoma (tumor grade from I to IV) were 0 (0/51), 3.9% (2/51), 5.9% (3/51), 13.7% (7/51), respectively. In contrast, the necrosis rates of unmethylated MGMT of osteosarcoma (tumor grade from I to IV) were 45.1% (23/51), 25.5% (13/51), 3.9% (2/51), 2.0% (1/51), respectively. It suggest that methylated and unmethylated MGMT gene of osteosarcoma have significant difference in protein expression. The unmethylated MGMT gene has higher positive protein expression (u = -4.92, P < 0.001). Methylation of MGMT gene has higher tumor necrosis rate in osteosarcoma patients. Methylation in MGMT promoter may be important for judging the effect of chemotherapy in Osteosarcoma patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21424568     DOI: 10.1007/s12253-010-9354-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  12 in total

1.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.

Authors:  Daniel J Weisenberger; Kimberly D Siegmund; Mihaela Campan; Joanne Young; Tiffany I Long; Mark A Faasse; Gyeong Hoon Kang; Martin Widschwendter; Deborah Weener; Daniel Buchanan; Hoey Koh; Lisa Simms; Melissa Barker; Barbara Leggett; Joan Levine; Myungjin Kim; Amy J French; Stephen N Thibodeau; Jeremy Jass; Robert Haile; Peter W Laird
Journal:  Nat Genet       Date:  2006-06-25       Impact factor: 38.330

2.  DNA hypermethylation status of multiple genes in soft tissue sarcomas.

Authors:  Ken-ichi Kawaguchi; Yoshinao Oda; Tsuyoshi Saito; Hidetaka Yamamoto; Tomonari Takahira; Chikashi Kobayashi; Sadafumi Tamiya; Naomi Tateishi; Yukihide Iwamoto; Masazumi Tsuneyoshi
Journal:  Mod Pathol       Date:  2006-01       Impact factor: 7.842

Review 3.  MGMT hypermethylation: a prognostic foe, a predictive friend.

Authors:  Filipe V Jacinto; Manel Esteller
Journal:  DNA Repair (Amst)       Date:  2007-05-07

4.  Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.

Authors:  G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

5.  Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.

Authors:  Verena Voelter; Annie-Claire Diserens; Alexandre Moulin; Georg Nagel; Pu Yan; Eugenia Migliavacca; Donata Rimoldi; Marie-France Hamou; Bernd Kaina; Serge Leyvraz; Monika E Hegi
Journal:  Int J Cancer       Date:  2008-09-01       Impact factor: 7.396

Review 6.  Potential and cytotoxicity of cis-platinum complex with anti-tumor activity in combination therapy.

Authors:  John W Ho
Journal:  Recent Pat Anticancer Drug Discov       Date:  2006-01       Impact factor: 4.169

Review 7.  O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy.

Authors:  Barbara Verbeek; Thomas D Southgate; David E Gilham; Geoffrey P Margison
Journal:  Br Med Bull       Date:  2008-02-01       Impact factor: 4.291

8.  Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma.

Authors:  Sun Lee; Woo Ho Kim; Hwoon-Yong Jung; Moon Ho Yang; Gyeong Hoon Kang
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

Review 9.  Cancer epigenetics: modifications, screening, and therapy.

Authors:  Einav Nili Gal-Yam; Yoshimasa Saito; Gerda Egger; Peter A Jones
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

Review 10.  DNA repair pathways as targets for cancer therapy.

Authors:  Thomas Helleday; Eva Petermann; Cecilia Lundin; Ben Hodgson; Ricky A Sharma
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

View more
  4 in total

1.  Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status.

Authors:  Jeremy M Rosenblum; N Ari Wijetunga; Melissa J Fazzari; Mark Krailo; Donald A Barkauskas; Richard Gorlick; John M Greally
Journal:  Epigenetics       Date:  2015-01-23       Impact factor: 4.528

2.  Aberrant DNA methylation of ESR1 and p14ARF genes could be useful as prognostic indicators in osteosarcoma.

Authors:  Viviane Sonaglio; Ana C de Carvalho; Silvia R C Toledo; Carolina Salinas-Souza; André L Carvalho; Antonio S Petrilli; Beatriz de Camargo; André L Vettore
Journal:  Onco Targets Ther       Date:  2013-06-17       Impact factor: 4.147

3.  Receptor interactive protein kinase 3 promotes Cisplatin-triggered necrosis in apoptosis-resistant esophageal squamous cell carcinoma cells.

Authors:  Yang Xu; Zhengwei Lin; Nan Zhao; Lanping Zhou; Fang Liu; Zbigniew Cichacz; Lin Zhang; Qimin Zhan; Xiaohang Zhao
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

4.  A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology.

Authors:  Kentaro Igarashi; Takashi Murakami; Kei Kawaguchi; Tasuku Kiyuna; Kentaro Miyake; Yong Zhang; Scott D Nelson; Sarah M Dry; Yunfeng Li; Jane Yanagawa; Tara A Russell; Arun S Singh; Hiroyuki Tsuchiya; Irmina Elliott; Fritz C Eilber; Robert M Hoffman
Journal:  Oncotarget       Date:  2017-07-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.